

1. REVLIMID [package insert]. Summit, NJ: Celgene Corp; 2019.
2. Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2019;37(14):1188-1199.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.5.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed October 20, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
4. Cabanillas F. Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? *J Clin Oncol*. 2013;31(1):14-16.
5. Yang ZZ, Ansell SM. The tumor microenvironment in follicular lymphoma. *Clin Adv Hematol Oncol*. 2012;10(12):810-818.
6. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. *J Clin Invest*. 2012;122(10):3424-3431.
7. Lackraj T, Goswami R, Kridel R. Pathogenesis of follicular lymphoma. *Best Pract Res Clin Haematol*. 2018;31(1):2-14.
8. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and T_H17 cells in B-cell non-Hodgkin's lymphoma. *Cancer Res*. 2009;69(13):5522-5531.
9. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. *J Clin Oncol*. 2018;37(2):144-152.
10. Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. www.pnas.org/cgi/doi/10.1073/pnas. Published online February 23, 2015. Accessed August 13, 2019.

11. Shafer D, Smith MR, Borghaei H, et al. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. *Leuk Res.* 2013;37(10):1213-1215.
12. Yang ZZ, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. *J Clin Invest.* 2012;122(4):1271-1282.
13. Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. *Blood.* 2009;114(21):4713-4720.
14. Link BK, Day B, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. *Br J Haematol.* 2019;184(4):660-663.
15. Alperovich A, Batlevi C, Smith K, et al. Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era. *Blood.* 2016;128(22):2955.
16. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. *Oncogene.* 2003;22:7359-7368.
17. Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. *Am J Cancer Res.* 2012;2(6):676-690.
18. Data on file. Celgene Corporation; 2018.